TNKS and hepatocellular carcinoma: However, the currently developed selective YAP activity inhibitors were clinically evaluated in other cancers such as non-small cell lung cancer and gastric cancer rather than HCC.391 Several agents target other pathways were found indirectly regulate Hippo/YAP signaling and against HCC, such as Statins (fluvastatin and simvastatin),400 Salvianolic acid B (Sal B)401 and Tankyrase inhibitor G007-LK.390 However, above unselective agents may exist potential off-target toxicity.